Abstract
The renin–angiotensin system is an important component of the cardiovascular system. Mounting evidence suggests that the metabolic products of angiotensin I and II — initially thought to be biologically inactive — have key roles in cardiovascular physiology and pathophysiology. This non-canonical axis of the renin–angiotensin system consists of angiotensin 1–7, angiotensin 1–9, angiotensin-converting enzyme 2, the type 2 angiotensin II receptor (AT2R), the proto-oncogene Mas receptor and the Mas-related G protein-coupled receptor member D. Each of these components has been shown to counteract the effects of the classical renin–angiotensin system. This counter-regulatory renin–angiotensin system has a central role in the pathogenesis and development of various cardiovascular diseases and, therefore, represents a potential therapeutic target. In this Review, we provide the latest insights into the complexity and interplay of the components of the non-canonical renin–angiotensin system, and discuss the function and therapeutic potential of targeting this system to treat cardiovascular disease.
| Original language | English |
|---|---|
| Pages (from-to) | 116-129 |
| Number of pages | 14 |
| Journal | Nature Reviews Cardiology |
| Volume | 17 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2020 |
Bibliographical note
Publisher Copyright:© 2019, Springer Nature Limited.
Funding
The authors received funding from Comisión Nacional de Ciencia y Tecnología (CONICYT), Chile (FONDAP 15130011 to M.P.O., J.A.R., L.G., M.C. and S.L.; FONDECYT 1161739 to J.E.J.; FONDECYT 11181000 to J.A.R.; FONDECYT 1140713 to L.G.), Grant Puente Pontificia Universidad Catolica de Chile (P1705/2017 to M.P.O.), Bayer AG (Program Grants4Targets ID 2017-08-2260 to M.P.O., J.E.J., M.C. and S.L.), and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil (310515/2015–7 to R.A.S.S.).
ASJC Scopus Subject Areas
- Cardiology and Cardiovascular Medicine
